<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pmv Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc</link>
<description>Latest news and press releases for Pmv Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pmv-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835aed578dffbe2df10efec.webp</url>
<title>Pmv Pharmaceuticals Inc</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc</link>
</image>
<item>
<title>PMV Pharmaceuticals Announces Board Chair Transition</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-board-chair-transition</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-board-chair-transition</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new ChairPRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been a</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights-30</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights-30</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer</description>
</item>
<item>
<title>New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM)</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-130000243</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-130000243</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 monthsRezatap</description>
</item>
<item>
<title>PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-updated-rezatapopt-153900550</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-updated-rezatapopt-153900550</guid>
<pubDate>Fri, 24 Oct 2025 15:39:00 GMT</pubDate>
<description>Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer coho</description>
</item>
<item>
<title>PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-present-rezatapopt-pivotal-200100608</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-present-rezatapopt-pivotal-200100608</guid>
<pubDate>Mon, 13 Oct 2025 20:01:00 GMT</pubDate>
<description>Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that</description>
</item>
<item>
<title>PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-promising-rezatapopt-110000996</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-promising-rezatapopt-110000996</guid>
<pubDate>Wed, 10 Sep 2025 11:00:00 GMT</pubDate>
<description>PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Applica</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-second-quarter-124200372</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-second-quarter-124200372</guid>
<pubDate>Thu, 07 Aug 2025 12:42:00 GMT</pubDate>
<description>PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP),</description>
</item>
<item>
<title>PMV Pharmaceuticals to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-participate-upcoming-investor-200500231</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-participate-upcoming-investor-200500231</guid>
<pubDate>Fri, 23 May 2025 20:05:00 GMT</pubDate>
<description>PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD C</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-first-quarter-120000240</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-first-quarter-120000240</guid>
<pubDate>Fri, 09 May 2025 12:00:00 GMT</pubDate>
<description>Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for approximately 50 patients with at least 18 weeks of follow-upCash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2025, providing expected cash runway to end of 2026 PRINCETON, N.</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-2024-130000703</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-2024-130000703</guid>
<pubDate>Mon, 03 Mar 2025 13:00:00 GMT</pubDate>
<description>Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed or refrac</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-2024-financial-results</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced</description>
</item>
<item>
<title>PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-provides-a-progress-update-on-pynnacle-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-provides-a-progress-update-on-pynnacle-clinical-trial</guid>
<pubDate>Wed, 23 Oct 2024 04:00:00 GMT</pubDate>
<description>Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-a-progress-update-on-pynnacle-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-a-progress-update-on-pynnacle-clinical-trial</guid>
<pubDate>Thu, 08 Aug 2024 04:00:00 GMT</pubDate>
<description>Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-first-quarter-2024-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-first-quarter-2024-financial-results-and-corporate-highlights</guid>
<pubDate>Thu, 09 May 2024 04:00:00 GMT</pubDate>
<description>First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and</description>
</item>
<item>
<title>PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-first-patient-dosed-in-global-tumor-agnostic-phase-2-pynnacle-trial-for-rezatapopt-in-tp53-y220c-positive-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-first-patient-dosed-in-global-tumor-agnostic-phase-2-pynnacle-trial-for-rezatapopt-in-tp53-y220c-positive-solid-tumors</guid>
<pubDate>Wed, 27 Mar 2024 04:00:00 GMT</pubDate>
<description>Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-year-2023-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-full-year-2023-financial-results-and-corporate-highlights</guid>
<pubDate>Thu, 29 Feb 2024 05:00:00 GMT</pubDate>
<description>Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy</description>
</item>
<item>
<title>PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-prioritization-of-pc14586-clinical-development-and-extended-cash-runway</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-announces-prioritization-of-pc14586-clinical-development-and-extended-cash-runway</guid>
<pubDate>Thu, 18 Jan 2024 05:00:00 GMT</pubDate>
<description>Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash</description>
</item>
<item>
<title>PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-strengthens-leadership-with-key-appointments-as-company-advances-into-late-stage-development</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-strengthens-leadership-with-key-appointments-as-company-advances-into-late-stage-development</guid>
<pubDate>Fri, 05 Jan 2024 05:00:00 GMT</pubDate>
<description>PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical</description>
</item>
<item>
<title>PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-2023-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/pmv-pharmaceuticals-inc/news/pmv-pharmaceuticals-reports-third-quarter-2023-financial-results-and-corporate-highlights</guid>
<pubDate>Thu, 09 Nov 2023 05:00:00 GMT</pubDate>
<description>Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer</description>
</item>
</channel>
</rss>